自己免疫疾患用IVDおよびLDT市場：技術別、用途別-2025-2030年の世界予測

自己免疫疾患用IVDおよびLDT市場は、2023年に172億7,000万米ドルと評価され、2024年には183億米ドルに達すると予測され、CAGR 5.22％で成長し、2030年には246億8,000万米ドルに達すると予測されています。

自己免疫疾患の体外診断薬（IVD）と臨床検査薬（LDT）の市場範囲には、自己免疫疾患の検出と監視を目的とした診断ツールや検査が含まれます。これらの検査の必要性は、関節リウマチ、狼瘡、多発性硬化症のような疾患に対応し、効果的な治療計画のために正確でタイムリーな診断を必要とする自己免疫疾患の有病率の増加によって強調されています。これらの診断薬は、主に病院、診断研究所、研究機関で応用され、臨床医、研究者、患者に貢献しています。主な成長促進要因としては、分子診断などの診断技術の進歩や個別化医療の台頭が挙げられます。さらに、ヘルスケア支出の増加、自己免疫疾患に罹患しやすい高齢者人口の増加、疾患の早期発見に対する意識の高まりが、市場の成長をさらに後押ししています。最新の潜在的ビジネスチャンスは、次世代シーケンシング（NGS）とポイントオブケア検査の進歩に明らかであり、業界各社は戦略的提携と技術革新を活用して検査の精度と信頼性を高めることができます。しかし、厳しい規制環境、高度な診断検査に関連する高コスト、自己免疫疾患の複雑性といった課題は、市場拡大の妨げとなる可能性があります。こうした課題を軽減するため、企業は、費用対効果が高く、迅速かつ高精度の診断ツールの開発、バイオマーカーの発見、予測診断のための人工知能の統合といったイノベーション分野に注力すべきです。市場は急速な技術進歩に牽引されながらダイナミックな競争を続けており、市場参入企業は継続的な研究開発を通じて動向を先取りすることが極めて重要です。満たされていない診断ニーズ、特に代表的でない自己免疫疾患に焦点を当て、診断薬へのアクセス性を世界的に高めることで、企業は持続可能な成長を達成することができます。規制状況、償還政策、技術統合の融合が市場の性質を形成し、既存の課題を克服し、新たな機会を活用するイノベーションの機が熟し、進化する市場情勢を浮き彫りにしています。

市場力学：急速に進化する自己免疫疾患用IVDおよびLDT市場の主要市場インサイトを公開

自己免疫疾患用IVDおよびLDT市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 各国における自己免疫疾患の増加
  • 自己免疫疾患の診断検査に対する意識の高まり
  • ヘルスケアインフラの整備と医療費の増加
• 市場抑制要因
  • 精神神経疾患以外の健康問題に対する懸念
• 市場機会
  • 体外診断用医薬品の分野における技術の進歩
  • 体外診断（IVD）検査キットの開発における共同開発の増加
• 市場の課題
  • 体外診断用医薬品とLDTに関する厳しい規制

ポーターのファイブフォース：自己免疫疾患用IVDおよびLDT市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：自己免疫疾患用IVDおよびLDT市場における外部からの影響の把握

外部マクロ環境要因は、自己免疫疾患用IVDおよびLDT市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析自己免疫疾患用IVDおよびLDT市場における競合情勢の把握

自己免疫疾患用IVDおよびLDT市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス自己免疫疾患用IVDおよびLDT市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、自己免疫疾患用IVDおよびLDT市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨自己免疫疾患用IVDおよびLDT市場における成功への道筋を描く

自己免疫疾患用IVDおよびLDT市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 経済における自己免疫疾患の発生率上昇
    • 自己免疫疾患の診断検査に関する意識の高まり
    • ヘルスケアインフラの発展とヘルスケア費の増加
  • 抑制要因
    • 神経精神医学以外の健康問題に関する懸念
  • 機会
    • IVD分野における技術の進歩
    • 体外診断（IVD）検査キットの開発に向けた協力関係の強化
  • 課題
    • IVDとLDTの厳格な規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 自己免疫疾患用IVDおよびLDT市場：技術別

• 臨床化学
• 凝固
• 血液学
• 免疫測定
• 微生物学
• 分子診断

第7章 自己免疫疾患用IVDおよびLDT市場：用途別

• アジソン病
• 円形脱毛症
• 強直性脊椎炎
• 抗リン脂質抗体症候群
• クローン病
• 1型糖尿病
• 多発性硬化症
• ナルコレプシー
• 乾癬
• 関節リウマチ
• 全身性エリテマトーデス
• 全身性強皮症
• 潰瘍性大腸炎
• ぶどう膜炎

第8章 南北アメリカの自己免疫疾患用IVDおよびLDT市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の自己免疫疾患用IVDおよびLDT市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの自己免疫疾患用IVDおよびLDT市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Adaptive Biotechnologies Corporation
• Agilent Technologies Inc.
• Bio-Rad Laboratories, Inc.
• bioMerieux, Inc.
• Corgenix, Inc.
• Creative Biolabs Inc.
• Diasorin S.P.A.
• in.vent Diagnostica GmbH
• Johnson & Johnson Services, Inc.
• Microbix Biosystems Inc.
• PerkinElmer, Inc.
• Roche Diagnostics Corporation
• SQI Diagnostics Inc.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET RESEARCH PROCESS
• FIGURE 2. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET DYNAMICS
• TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COAGULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ALOPECIA AREATA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTIPHOSPHOLIPID ANTIBODY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIABETES TYPE 1, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY NARCOLEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 51. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 73. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 88. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 116. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

The IVD & LDT For Autoimmune Diseases Market was valued at USD 17.27 billion in 2023, expected to reach USD 18.30 billion in 2024, and is projected to grow at a CAGR of 5.22%, to USD 24.68 billion by 2030.

The market scope for In Vitro Diagnostics (IVD) and Laboratory Developed Tests (LDT) for autoimmune diseases involves diagnostic tools and tests designed to detect and monitor autoimmune conditions. The necessity of these tests is underscored by the increasing prevalence of autoimmune disorders, which demand precise and timely diagnosis for effective treatment plans, addressing disorders like rheumatoid arthritis, lupus, and multiple sclerosis. These diagnostics are applied primarily in hospitals, diagnostic laboratories, and research institutions, serving clinicians, researchers, and patients. A key growth driver includes advancements in diagnostic technologies such as molecular diagnostics and the rise in personalized medicine. Additionally, increasing healthcare expenditure, a growing geriatric population susceptible to autoimmune conditions, and rising awareness of early disease detection further fuel market growth. Latest potential opportunities are apparent in next-generation sequencing (NGS) and point-of-care testing advancements, where industry players can leverage strategic collaborations and technological innovations to enhance test accuracy and reliability. However, challenges such as stringent regulatory environments, high costs associated with advanced diagnostic tests, and the complexity of autoimmune diseases can hinder market expansion. To mitigate these challenges, companies should focus on innovation areas such as developing cost-effective, rapid, and highly accurate diagnostic tools, biomarker discovery, and integrating artificial intelligence for predictive diagnostics. The market remains dynamic and competitive, driven by rapid technological advancements, making it crucial for market participants to stay ahead of trends through continuous research and development. By focusing on unmet diagnostic needs, particularly in under-represented autoimmune disorders, and enhancing the accessibility of diagnostics globally, businesses can achieve sustainable growth. The convergence of regulatory approvals, reimbursement policies, and technological integrations shapes the market's nature, highlighting an evolving landscape ripe for innovations that can navigate existing challenges and capitalize on emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving IVD & LDT For Autoimmune Diseases Market

The IVD & LDT For Autoimmune Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of autoimmune disorders in economies
  • Increasing awareness regarding diagnostic tests for autoimmune diseases
  • Rising development of healthcare infrastructure and growing healthcare expenditure
• Market Restraints
  • Concerns regarding extra-neuropsychiatric health problems
• Market Opportunities
  • Technological advancements in the field of IVD
  • Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
• Market Challenges
  • Stringent regulations of IVDs & LDTs

Porter's Five Forces: A Strategic Tool for Navigating the IVD & LDT For Autoimmune Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the IVD & LDT For Autoimmune Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the IVD & LDT For Autoimmune Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the IVD & LDT For Autoimmune Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the IVD & LDT For Autoimmune Diseases Market

A detailed market share analysis in the IVD & LDT For Autoimmune Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the IVD & LDT For Autoimmune Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the IVD & LDT For Autoimmune Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the IVD & LDT For Autoimmune Diseases Market

A strategic analysis of the IVD & LDT For Autoimmune Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the IVD & LDT For Autoimmune Diseases Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., bioMerieux, Inc., Corgenix, Inc., Creative Biolabs Inc., Diasorin S.P.A., in.vent Diagnostica GmbH, Johnson & Johnson Services, Inc., Microbix Biosystems Inc., PerkinElmer, Inc., Roche Diagnostics Corporation, SQI Diagnostics Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the IVD & LDT For Autoimmune Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Clinical Chemistry, Coagulation, Hematology, Immunoassays, Microbiology, and Molecular Diagnostics.
• Based on Application, market is studied across Addison's Disease, Alopecia Areata, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Crohn's Disease, Diabetes Type 1, Multiple Sclerosis, Narcolepsy, Psoriasis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Ulcerative Colitis, and Uveitis.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of autoimmune disorders in economies
    • 5.1.1.2. Increasing awareness regarding diagnostic tests for autoimmune diseases
    • 5.1.1.3. Rising development of healthcare infrastructure and growing healthcare expenditure
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding extra-neuropsychiatric health problems
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in the field of IVD
    • 5.1.3.2. Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations of IVDs & LDTs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. IVD & LDT For Autoimmune Diseases Market, by Technology

• 6.1. Introduction
• 6.2. Clinical Chemistry
• 6.3. Coagulation
• 6.4. Hematology
• 6.5. Immunoassays
• 6.6. Microbiology
• 6.7. Molecular Diagnostics

7. IVD & LDT For Autoimmune Diseases Market, by Application

• 7.1. Introduction
• 7.2. Addison's Disease
• 7.3. Alopecia Areata
• 7.4. Ankylosing Spondylitis
• 7.5. Antiphospholipid Antibody Syndrome
• 7.6. Crohn's Disease
• 7.7. Diabetes Type 1
• 7.8. Multiple Sclerosis
• 7.9. Narcolepsy
• 7.10. Psoriasis
• 7.11. Rheumatoid Arthritis
• 7.12. Systemic Lupus Erythematosus
• 7.13. Systemic Sclerosis
• 7.14. Ulcerative Colitis
• 7.15. Uveitis

8. Americas IVD & LDT For Autoimmune Diseases Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific IVD & LDT For Autoimmune Diseases Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa IVD & LDT For Autoimmune Diseases Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptive Biotechnologies Corporation
• 2. Agilent Technologies Inc.
• 3. Bio-Rad Laboratories, Inc.
• 4. bioMerieux, Inc.
• 5. Corgenix, Inc.
• 6. Creative Biolabs Inc.
• 7. Diasorin S.P.A.
• 8. in.vent Diagnostica GmbH
• 9. Johnson & Johnson Services, Inc.
• 10. Microbix Biosystems Inc.
• 11. PerkinElmer, Inc.
• 12. Roche Diagnostics Corporation
• 13. SQI Diagnostics Inc.
• 14. Thermo Fisher Scientific Inc.